A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer

Abstract Purpose Notch signaling dysregulation is implicated in the development of pancreatic adenocarcinoma (PDAC). Tarextumab is a fully human IgG2 antibody that inhibits Notch2/3 receptors. Patients and Methods Aphase 2, randomized, placebo‐controlled, multicenter trial evaluated the activity of...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Zishuo Ian Hu, Johanna C. Bendell, Andrea Bullock, Noelle K. LoConte, Hassan Hatoum, Paul Ritch, Hugo Hool, Joseph W. Leach, James Sanchez, Davendra P. S. Sohal, John Strickler, Ravindranath Patel, Andrea Wang‐Gillam, Irfan Firdaus, Kenneth H. Yu, Ann M. Kapoun, Eric Holmgren, Lei Zhou, Jakob Dupont, Vincent Picozzi, Vaibhav Sahai, Eileen M. O'Reilly
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2019-09-01
Serie:	Cancer Medicine
Soggetti:	cancer stem cell gemcitabine nab‐paclitaxel Notch 2/3 receptor inhibitor Pancreatic cancer tarextumab
Accesso online:	https://doi.org/10.1002/cam4.2425
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!